A Phase 3 interventional study of DWP16001 0.3 mg in T2DM (Type 2 Diabetes Mellitus), sponsored by Daewoong Pharmaceutical Co. LTD.. Not yet recruiting. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2023-11-21.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 4 of them phase 3. Enavogliflozin · Diabetes Mellitus, Type 2.
Among the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, this one is the 9th largest by planned enrollment, is one of 4 that started in 2023, is one of 8 in phase 3, and was the 11th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:
Korea University Anam Hospital · Sites in Korea, Republic of
Ages 20–79
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 20–80
Yonsei University · Sites in Korea, Republic of
Ages 19+
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–80 · Healthy volunteers
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 19 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 4 started in 2023.
This study's planned enrollment of 134 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 140 across the 15 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 15 have an industry lead sponsor. The 4 most frequent:
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
20 studies in Diabetes Mellitus, Type 2 by Daewoong Pharmaceutical Co. LTD.: 6 open now, 10 under way, 4 of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 20 studies in Diabetes Mellitus, Type 2 by Daewoong Pharmaceutical Co. LTD., this one is the 11th largest by planned enrollment of the 16 interventional ones that give a count, is one of 5 that started in 2023, is one of 10 in phase 3, and was the 15th registered.
Daewoong Pharmaceutical Co. LTD.’s Diabetes Mellitus, Type 2 studies by the year they started, since 2015.
2 of the studies testing enavogliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07619833Phase 3Daewoong Pharmaceutical Co. LTD.To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus | 2027-11 |
| NCT06399835Seoul National University Bundang HospitalEnavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Daewoong Pharmaceutical Co. LTD.’s 20 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The subjects, having voluntarily agreed to participate in the clinical trial and provided informed consent, will undergo screening tests. During Visit 1 (Screening), subjects meeting the inclusion/exclusion criteria will go through an 8-week stabilization period.
At Visit 1-1, central laboratory tests will be conducted. If the test results meet the criteria for Visit 2 (Enrollment Visit), the subject will be eligible to participate in the clinical trial.
The subjects will receive the investigational drug (DWP16001 0.3 mg) once a day for 52 weeks. They will visit the clinical trial site at weeks 8, 16, 24, 38, and 52 for safety and efficacy assessments during the 52-week treatment period.
The subjects, having voluntarily agreed to participate in the clinical trial and provided informed consent, will undergo screening tests. During Visit 1 (Screening), subjects meeting the inclusion/exclusion criteria will go through an 8-week stabilization period. Throughout this period, subjects will receive concurrent administration of metformin (≥1,000 mg/day) and gemigliptin (50 mg/day), and will have a washout period for other oral antidiabetic drugs.
At Visit 1-1, central laboratory tests will be conducted. If the test results meet the criteria for Visit 2 (Enrollment Visit), the subject will be eligible to participate in the clinical trial.
The subjects will receive the investigational drug (DWP16001 0.3 mg) once a day for 52 weeks. They will visit the clinical trial site at weeks 8, 16, 24, 38, and 52 for safety and efficacy assessments during the 52-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DWP16001 0.3mg, Tablets, Orally, Once daily
Drug: DWP16001 0.3 mg
DWP16001 0.3mg, Tablets, Orally, Once daily
Safety outcomes_Adverse events occurred during clinical trials
Safety outcomes_Adverse events occurred during clinical trials
Time frame: from baseline up to 52 weeks
Safety outcomes_ Change of blood pressure
Safety outcomes_ Change of blood pressure
Time frame: from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP
Safety outcomes_ Change of heartbeat
Safety outcomes_ Change of heartbeat
Time frame: from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP
Safety outcomes_ Change of body temperature
Safety outcomes_ Change of body temperature
Time frame: from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP
Efficacy outcome_Change of HbA1c
Efficacy outcome_Change of HbA1c
Time frame: from Baseline at Week 8, 16, 24, 38, and 52 after administration of the IP
Efficacy outcome_Change of FPG
Efficacy outcome_Change of FPG
Time frame: from baseline at Week 8, 16, 24, 38, and 52 after administration of the IP
Efficacy outcome_Proportion of subjects achieving HbA1c target of < 6.5%
Efficacy outcome_Proportion of subjects achieving HbA1c target of \< 6.5%
Time frame: at Weeks 8, 16, 24, 38 and 52 after administration of the IP
Efficacy outcome_Proportion of subjects achieving HbA1c target of < 7.0 %
Efficacy outcome_Proportion of subjects achieving HbA1c target of \< 6.5%
Time frame: at Weeks 8, 16, 24, 38 and 52 after administration of the IP
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2023; primary completion for Sep 2025, 21 months later.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 21 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enavogliflozin
Daewoong Pharmaceutical Co. LTD. →